Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

RET fusion as a novel driver of medullary thyroid carcinoma.

Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ.

J Clin Endocrinol Metab. 2015 Mar;100(3):788-93. doi: 10.1210/jc.2014-4153. Epub 2014 Dec 29.

2.

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.

Ji JH, Oh YL, Hong M, Yun JW, Lee HW, Kim D, Ji Y, Kim DH, Park WY, Shin HT, Kim KM, Ahn MJ, Park K, Sun JM.

PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015 Aug.

3.

A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.

Johanson V, Ahlman H, Bernhardt P, Jansson S, Kölby L, Persson F, Stenman G, Swärd C, Wängberg B, Stridsberg M, Nilsson O.

Endocr Relat Cancer. 2007 Jun;14(2):433-44.

PMID:
17639056
4.

Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.

Kihara M, Miyauchi A, Yoshioka K, Oda H, Nakayama A, Sasai H, Yabuta T, Masuoka H, Higashiyama T, Fukushima M, Ito Y, Kobayashi K, Miya A.

Auris Nasus Larynx. 2016 Oct;43(5):551-5. doi: 10.1016/j.anl.2015.12.016. Epub 2016 Feb 1.

PMID:
26837867
5.

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L.

J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5. doi: 10.1210/jc.2012-2092. Epub 2012 Aug 3.

6.
7.

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

Moura MM, Cavaco BM, Pinto AE, Leite V.

J Clin Endocrinol Metab. 2011 May;96(5):E863-8. doi: 10.1210/jc.2010-1921. Epub 2011 Feb 16.

PMID:
21325462
8.

Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F.

J Clin Endocrinol Metab. 1996 Apr;81(4):1619-22.

PMID:
8636377
9.

Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.

Yamamoto H, Ishii J, Chiba T, Nakazato Y, Hirano K, Kamma H.

Pathol Int. 2017 Nov;67(11):580-584. doi: 10.1111/pin.12588. Epub 2017 Sep 27.

PMID:
28952196
10.

Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Chu YH, Lloyd RV.

Endocr Pathol. 2016 Dec;27(4):312-324. Review.

PMID:
27539727
11.

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.

Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M.

Anticancer Res. 2011 Dec;31(12):4179-83.

PMID:
22199277
12.

Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.

Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.

Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7.

PMID:
7641404
13.

The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.

Oczko-Wojciechowska M, Pfeifer A, Rusinek D, Pawlaczek A, Zebracka-Gala J, Kowalska M, Kowal M, Swierniak M, Krajewska J, Gawlik T, Chmielik E, Czarniecka A, Szpak-Ulczok S, Jarząb B.

Endokrynol Pol. 2015;66(2):121-5. doi: 10.5603/EP.2015.0018.

14.

Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.

van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ, Höppener JW.

Cancer Res. 2008 Mar 1;68(5):1329-37. doi: 10.1158/0008-5472.CAN-07-5754.

15.

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

Vanden Borre P, Schrock AB, Anderson PM, Morris JC 3rd, Heilmann AM, Holmes O, Wang K, Johnson A, Waguespack SG, Ou SI, Khan S, Fung KM, Stephens PJ, Erlich RL, Miller VA, Ross JS, Ali SM.

Oncologist. 2017 Mar;22(3):255-263. doi: 10.1634/theoncologist.2016-0279. Epub 2017 Feb 16.

16.

Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.

Rodríguez-Antona C, Muñoz-Repeto I, Inglada-Pérez L, de Cubas AA, Mancikova V, Cañamero M, Maliszewska A, Gómez A, Letón R, Leandro-García LJ, Comino-Méndez I, Sanchez L, Alvarez-Escolá C, Aller J, Cascón A, Robledo M.

Endocr Relat Cancer. 2013 Jul 12;20(4):611-9. doi: 10.1530/ERC-12-0316. Print 2013 Aug.

PMID:
23780998
17.

RAS proto-oncogene in medullary thyroid carcinoma.

Moura MM, Cavaco BM, Leite V.

Endocr Relat Cancer. 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. Review.

PMID:
26285815
18.

Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma.

Guerrero IM, Pessoa CH, Olmedo DB, Pontes ER, Matos LC, Tilli TM, Barcinski MA, Gimba ER.

Thyroid. 2006 Jan;16(1):9-15.

PMID:
16487008
19.

Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.

Borrello MG, Aiello A, Peissel B, Rizzetti MG, Mondellini P, Degl'Innocenti D, Catalano V, Gobbo M, Collini P, Bongarzone I, Pierotti MA, Greco A, Seregni E.

Endocr Relat Cancer. 2011 Jul 25;18(4):519-27. doi: 10.1530/ERC-10-0306. Print 2011 Aug.

PMID:
21690267
20.

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Romei C, Ciampi R, Elisei R.

Nat Rev Endocrinol. 2016 Apr;12(4):192-202. doi: 10.1038/nrendo.2016.11. Epub 2016 Feb 12. Review.

PMID:
26868437

Supplemental Content

Support Center